Antibody Engineering.
Minimize Immunogenicity.
Advancements in protein sequencing technologies make it possible to work off of the exact amino acid sequence of any antibody species, allowing easy modification. This knowledge both enables and simplifies grafting any host regions of interest onto a desired backbone.
Next generation protein sequencing (NGPS) continues to facilitate recombinant expression to ease manipulation and engineering. More importantly, when modifications, mispairings, or mutations occur through time, proteomics can also help confirm the protein sequence in every step throughout the therapeutic pipeline.
Research teams are using NGPS for therapeutic and diagnostic projects focused on humanization and/or chimerization of antibodies, development of nanobodies, scFvs, and/or engineering of bi/tri/multi-specific antibodies.
Services for Antibody Engineering.
We support the antibody engineering efforts of life science companies in all stages of development. Contact Us to discover how we can help with your antibody engineering application.
Antibody Sequencing & Discovery Services.
de novo mAb Sequencing
Obtain amino acid sequences of functional antibodies to facilitate in silico design, rational engineering, humanization, chimerization, affinity maturation, conjugation design and construction of fragments and multi-specifics.
Explore REmAb
Novel mAb Discovery
Mine the functional native immune response by directly sequencing and accessing patient antibodies and discover novel mAb candidates for downstream engineering efforts.
Explore REpAb
Validate Engineered mAb Constructs
Confirm protein sequences and pinpoint the occurrences of any modifications, mispairings, or mutations after protein expression or during cell line development. Minimize troubleshooting efforts with real-time peptide mapping.
Explore MATCHmAb
Binding Kinetics
Test, assess, and evaluate mAb binding kinetic properties (ie. specificity, affinity, efficiency) to evaluate and reevaluate engineering strategies.
Explore SPR Analysis
Epitope Mapping
Characterize antigenic epitopes for the rational design of mAbs, scFvs, and multi-specifics. Determine antibody binding sites on target antigens for FDA and EMEA regulatory filings and IP protection.
Explore HDX-MS
Recombinant Expression
Indefinitely store the amino acid sequence and recombinantly express the engineered mAb in a streamlined workflow, securing product supply.
Explore Antibody Expression
Application Publications.
Latest Advancements in Antibody Engineering – Bispecifics, Diagnostic Controls, and More
September 28, 10:00 EST In this webinar, you will learn: Antibody technologies for the [...]
Antibody Discovery Dead Ends and New Approaches
In this webinar, you will learn: About the challenges commonly encountered in antibody discovery [...]
Single-Molecule Characterization of Subtype-Specific β1 Integrin Mechanics
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
CAR-iNKT Cells Targeting Clonal TCRVβ Chains as a Precise Strategy to Treat T Cell Lymphoma
With 22 functional T cell receptor (TCR)Vβ subunit families making up the normal T cell repertoire, signals from these cell surface receptors often determine the fate of normal cells. However, mutations in TCR signaling proteins are frequently associated with peripheral T cell lymphomas (TCLs), including adult T cell leukemia/lymphoma (ATL), which indicates a driving role for TCRs in TCL oncogenesis. As TCL and ATL are clonal in nature, tumour cells typically express a single TCRVβ subunit with no bias in the usage of TCRVβ subunit families. Consequently, targeting the specific TCRVβ subunit presents a promising therapeutic approach that is highly selective and tumour-specific.
“We’re focused on coupling cytokines with a highly engineered VHVL of an antibody. So by sequencing the antibodies with Rapid Novor we are able to pull out the CDR to graft them into our platform and test in vitro and in vivo.”
Pavel Khrimian – Co-founder and CBO, Deka Biosciences
Talk to Our Scientists.
We Have Sequenced 8000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.
Talk to Our Scientists.
We Have Sequenced 8000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics